Eli Lilly Launches New Multidose Zepbound KwikPen for Weight Loss

Eli Lilly has officially launched a new, more convenient way for patients to take its blockbuster obesity medication: the multidose Zepbound KwikPen.

Following a recent label expansion approved by the Food and Drug Administration (FDA), this single-patient device contains a full four-week supply of the weight-loss medication. Previously, patients utilizing Zepbound (tirzepatide) had to rely on a different single-dose auto-injector for each weekly injection or manually draw the medicine from vials. The introduction of the KwikPen significantly reduces the number of devices patients must manage each month, offering a much more streamlined and convenient user experience.

Currently, the device is available to self-paying patients through LillyDirect, the company’s direct-to-consumer platform. Prices start at $299 per month for the initial 2.5-milligram dose. Following a recent agreement with the Trump administration aimed at aligning U.S. drug costs with European markets, Lilly confirmed that the self-pay price for the KwikPen will not exceed $449 in the United States. This price cap represents a $50 discount from the previous direct-to-patient costs.

The rollout is part of Eli Lilly’s strategy to sustain the massive momentum of Zepbound, which has experienced explosive demand since hitting the market in late 2023. During the fourth quarter of 2025 alone, Zepbound generated $4.2 billion in U.S. revenue—a staggering 122% spike from the previous year. It is now recognized as the number one prescribed injectable obesity-management medication.

The drug's soaring popularity is heavily backed by its strong clinical efficacy. In the SURMOUNT-5 clinical trial, patients lost an average of up to 50 pounds (or 20.2% of their body weight). Ilya Yuffa, president of Lilly USA, emphasized that the KwikPen release reinforces the company's "commitment to supporting people living with obesity in their weight management journey".

However, Lilly strictly notes that Zepbound is not for cosmetic weight loss. The drug tackles underlying causes of excess weight and is indicated for adults with obesity or overweight individuals with weight-related medical conditions, including moderate-to-severe obstructive sleep apnea. It also carries warnings for potential severe side effects, ranging from gastrointestinal distress to a risk of thyroid tumors.

---

🔖 Sources

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen

Lilly adds multidose Zepbound pens to self-pay menu after FDA nod

---

Keywords: Multidose Zepbound KwikPen

Multidose Zepbound KwikPen

---